Table 5 Course of patients, oxygen therapy after administration of tocilizumab on day 2 and day 30
From: Safety and efficacy of tocilizumab in critically ill patients with COVID-19: an observational study
O2 therapy before tocilizumab | O2 therapy after tocilizumab on day 2 | Follow-up oxygen therapy/outcome after on day 30 | |
|---|---|---|---|
O2 therapy (N = 50) | NRHF (N = 38) | Nasal cannula (3–6L) (N = 16) | Discharged on room air (N = 9) |
Discharged on domiciliary O2(N = 7) | |||
Face mask (≥ 10L) (N = 8) | Died (N = 1) | ||
MV (N = 2) | |||
Discharged on room air (N = 2) | |||
Discharged on domiciliary O2 (N = 3) | |||
CPAP (N = 7) | MV (N = 4) | ||
Discharged on domiciliary O2 (N = 3) | |||
MV (N = 4) | Died (N = 4) | ||
Died (N = 3) | |||
Nasal cannula (3–6L) (N = 8) | Nasal cannula (< 3L) (N = 4) | Discharged on room air (N = 3) | |
Discharged on domiciliary O2 (N = 1) | |||
NRHF (N = 2) | MV (N = 1) | ||
Discharged on domiciliary O2 (N = 1) | |||
CPAP (N = 1) | MV (N = 1) | ||
MV (N = 1) | Died (N = 1) | ||
CPAP (N = 4) | Nasal cannula (3–6L) (N = 1) | Discharged on room air (N = 1) | |
MV (N = 1) | Died (N = 1) | ||
Died (N = 2) | |||